EP 2043606 A2 20090408 - NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
Title (en)
NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
Title (de)
NANOPARTIKELFÖRMIGE KINASEHEMMERFORMULIERUNGEN
Title (fr)
FORMULATIONS D'INHIBITEURS DE KINASE NANOPARTICULAIRES
Publication
Application
Priority
- US 2007071011 W 20070612
- US 81296006 P 20060613
Abstract (en)
[origin: WO2007146943A2] The invention is directed to compositions comprising at least one nanop articulate kinase inhibitor, such as LS 104 or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate kinase inhibitor particles, such as LS 104, have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancers, such as leukemia, myeloproliferative disorders and related diseases.
IPC 8 full level
CPC (source: EP KR)
A61K 9/0019 (2013.01 - EP); A61K 9/14 (2013.01 - KR); A61K 9/145 (2013.01 - EP); A61K 9/146 (2013.01 - EP); A61K 9/20 (2013.01 - KR); A61K 9/2009 (2013.01 - EP); A61K 9/2013 (2013.01 - EP); A61K 9/2018 (2013.01 - EP); A61K 9/2054 (2013.01 - EP); A61K 47/32 (2013.01 - EP); A61P 35/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP); B82Y 5/00 (2013.01 - KR)
Citation (search report)
See references of WO 2007146943A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
WO 2007146943 A2 20071221; WO 2007146943 A3 20080529; AU 2007257667 A1 20071221; CA 2654909 A1 20071221; CN 101500540 A 20090805; EP 2043606 A2 20090408; JP 2009540010 A 20091119; KR 20090018864 A 20090223; TW 200816987 A 20080416
DOCDB simple family (application)
US 2007071011 W 20070612; AU 2007257667 A 20070612; CA 2654909 A 20070612; CN 200780029884 A 20070612; EP 07798449 A 20070612; JP 2009515607 A 20070612; KR 20097000297 A 20090107; TW 96121317 A 20070613